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Objective/background: Viral hepatitis, particularly hepatitis B virus (HBV) and hepatitis C
virus (HCV), infections and tuberculosis (TB) are a global public health concern.
Co-infection with HBV or HCV among TB patients may potentiate the risk of hepatotoxicity
induced by anti-TB drugs. Hence, the aim of this study was to identify the prevalence of
HBV and HCV among TB patients included in the Duhok National Tuberculosis Program
(NTP). Methods: The Duhok NTP Center is a specialized institution in Duhok City, Iraq,
concerned with management and follow-up of TB patients. A cross-sectional study was
conducted at the center between June 2015 and May 2016. All documented TB patients were
analyzed on the basis of socio-demographic and other characteristics. Thereafter, all
patients underwent screening for hepatitis B surface antigen (HBsAg), anti-HCV, and
anti-HIV using enzyme-linked immunosorbent assay (ELISA). The results obtained were
analyzed by entering the data in binary format into a Microsoft Excel spreadsheet. A p value
of <.05 was considered to be statistically significant. Results: Two-hundred fourteen docu-
mented TB patients were recruited in this study, with 127 (59.3%) males and 87 (40.7%)
females. The mean age of the patients was 40.34 years (±20.29). Of the total number of
patients, four cases (1.8%) were HBsAg-positive and one case (0.9%) was positive for
anti-HCV. The variables significantly associated with HBV were history of surgical dental
procedure [odds ratio (OR), 0.04; 95% confidence interval (CI), 0.01 to 0.04; p = .03], and
nationality (OR, 13.67; 95% CI, 0.46–210.85; p = .007). Conclusion: The prevalence of HBV
and HCV co-infection among TB patients in this study was low. This may be explained
by the low rate of blood transfusion among the patients, the very low prevalence of HIV
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universal infection-control measures, including vaccination for HBV. Both history of dental
intervention and belonging to a Syrian population were independent risk factors for HBV/
TB co-infection.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Viral hepatitis, particularly hepatitis B virus (HBV) and hepati-
tis C virus (HCV) infections, are a global public health concern
because they are the leading cause of chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma. HBV infects around
one-third of the world population, with 400 million patients
that are chronically infected [1]. Chronic HCV infection also
affects approximately 170 million individuals, that is, 2.5%
of the world population [2]. Hepatitis B and C show great
diversity in their prevalence in different parts of the world.
The World Health Organization reports a prevalence of HBV
and HCV infections in the eastern Mediterranean region of
2–4% and 1–4.6%, respectively [3]. Studies on the general pop-
ulation in Iraq for the years 2006 and 2007 revealed a preva-
lence of 1.6% and 0.04% for HBV and HCV, respectively [4].
Tuberculosis (TB) has also emerged as a serious public health
problem; it is recognized alongside HIV as a leading cause of
death worldwide. In 2014, TB caused 9.6 million new cases
and killed 1.5 million people [5]. According to a recent report
by the World Health Organization, Iraq is a relatively high-
TB-burden country in the eastern Mediterranean region, with
an estimated incidence rate of 43/100,000 and a case-
detection rate of 54% [5]. The war and the unstable security
situation in Iraq make access to healthcare facilities difficult.
Hence, maintaining treatment and follow-up for TB patients
is a priority, especially for patients who have fled their home
and subsequently discontinued treatment, and for locations
with low case-detection rate. Drug-induced hepatotoxicity is
a recognized side effect of anti-TB drugs, particularly rifampi-
cin, isoniazid, and pyrazinamide. TB patients with HBVand/or
HCV co-infections have increased susceptibility to the poten-
tial hepatotoxic effects of first-line anti-TB drugs and thus
may require discontinuation of their treatment [6].
Therefore, chronic liver disease in patients with TB makes
TB treatment challenging. Hence, the present cross-sectional
study was done to identify the prevalence of HBV and HCV
infections in TB patients at the Duhok National Tuberculosis
Program (NTP) Center. To our knowledge, this is the first study
on the prevalence of HBV and HCV infections among TB
patients in Iraq.
Patients and methods
Setting
The Tuberculosis Respiratory Diseases Consultation Center, or
NTP center, is a specialized institution in Duhok City con-
cerned with management and follow-up of TB patients. It isprovided with a laboratory, an X-ray unit [i.e., a chest X-ray
(CXR) unit], and pharmacy mainly for anti-TB drugs. It is
responsible for all TB cases in the governorate, engaging in
supervision and implementation of the Directly Observed
Treatment, Short-Course (DOTS) program.
Study design and patients
The study was conducted at the NTP Center in Duhok
Province between June 2015 and May 2016. All documented
pulmonary and extrapulmonary TB patients, who were con-
firmed by standard protocol using acid-fast-bacilli smear
microscopy, GenXpert molecular assay, radiological examina-
tion, and/or biopsy, were included in the study. Patients were
included in the study after obtaining written informed con-
sent. Information on socio-demographic and other patient
characteristics was collected by using a standard
questionnaire.
Laboratory diagnostic testing for HBsAg and anti-HCV
All patients underwent screening for hepatitis B surface anti-
gen (HBsAg), anti-HCV, and anti-HIV using enzyme-linked
immunosorbent assay (ELISA). Two 5-mL samples of blood
for detection of HBV and HCV markers were taken from each
participant. Serum specimens were tested for HBsAg and
anti-HCV by ELISA (Fortress Diagnostics Limited, Antrim,
UK) according to manufacturer instructions [7,8].
Statistical analysis
The results obtained were analyzed by entering the data in
binary format into a Microsoft Excel spreadsheet. A p value
of <.05 was considered to be statistically significant.
Results
A total of 214 patients with TB attending the TB services at the
NTP center Duhok were enrolled in this study. The mean age
of the patients was 40.34 years (±20.29); 127 (59.3%) were male
and 87 (40.7%) were female, giving a sex ratio of 1.46:1. Of the
total patients, 155 (72.4%) were new TB cases and 59 (27.6%)
were previously treated patients. The majority of TB patients
had pulmonary manifestation (197, 92.1%) and were of Iraqi
nationality (97.2, 97.2%; Table 1).
Out of the 214 TB patients recruited in the study, four cases
(1.8%) were HBsAg-positive and one case (0.9%) was positive
for anti-HCV. None of the TB patients had HBV and HCV co-
infection (Table 2, Fig. 1). Table 3 shows the number and crude
Table 1 – Characteristics of 214 tuberculosis cases in Duhok Province, Kurdistan.
Parameter Variable Number Percentage (%)
Age Mean age 40.34 ± 20.29
Gender Male 127 59.3
Female 87 40.7
Type of patient New cases 155 72.4
Previous TB treatment 59 27.6
Site of disease Pulmonary 197 92.1
Extrapulmonary 17 7.9
Region of origin Iraq 208 97.2
Others (Syria, Turkey) 6 2.8
Fig. 1 – Overall prevalence of HBVand HCV infections among
tuberculosis patients (N = 214).
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The variables significantly associated with HBV were history
of surgical dental procedure [odds ratio (OR), 0.04; 95% confi-
dence interval (CI), 0.01 to 0.04; p = .03] and nationality (OR,
13.67; 95% CI, 0.46–210.85; p = .007; Table 3).
Discussion
HBV and HCV co-infection among TB patients undergoing
anti-TB treatment may increase the risk of drug-induced hep-
atotoxicity. Hence, we conducted this study to identify the
frequency of HBV and HCV infection among TB patients. In
our study, four TB cases (1.87%) were found to be co-
infected with HBV, and one case (0.47%) with HCV. The preva-
lence of HBV infection in this study was lower than that
reported in most previous studies. Reported prevalence rates
are 26.8% in Rio de Janeiro, Brazil [9], and 19.8% in Argentina
[10]. Studies in Georgia [11] and Taiwan [6] showed prevalence
rates of 13% and 11.7%, respectively. It is noteworthy that a
substantial number of TB patients with HBV infection had
concomitant HIV infection in the aforementioned studies.
Hence, the variations in the prevalence between our study
and the studies done abroad may be partially explained by
the markedly lower prevalence of HIV infection in our popula-
tion. An explanation for the low rate of HBV observed in our
study is the adherence to universal infection-control mea-
sures, including HBV vaccination. Our study also revealed a
low HCV sero-prevalence among TB patients. There are wide
variations in the prevalence of HCV among HCV co-infected
TB patients reported in studies from different countries: An
HCV frequency as high as 31% was reported in Thailand
[12]. The reported prevalence is 7.5% in Central Brazil [13]
and 22% in Georgia and Pakistan [14,15]. Kuniholm et al.
[11], Wan et al. [6], and Khalili et al. [16] found prevalence
rates of 12%, 6.7%, and 27.45%, respectively. A study by
Badawy et al. that involved 135 TB patients revealed an HCV
co-infection rate of 6.4% [17]. These variations may reflectTable 2 – Demographic profiles of tuberculosis patients co-infec
Serological marker Number
HBsAg 4
Anti-HCV 1
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitisregional differences in the prevalence of hepatitis C infection,
the differential use of diagnostic modalities [ELISA, poly-
merase chain reaction (PCR), recombinant immunoblot assay
(RIBA)], or both. The low HCV sero-prevalence in our study
could be explained by the fact that our study population
had no history of injection drug use and that only a small
number of patients had received a blood transfusion. In
agreement with this finding, in 2014 a low HCV sero-
prevalence (0.14) was reported among patients who under-
went elective surgery at Duhok Emergency Hospital [18].
In general, patients in our study are young, which is in
agreement with other studies [19] and confirms that TB is a
disease of economically productive age groups. In the study,
an age of around 43 years is associated with HBV infection,
consistent with a similar study on Iraqi patients [20]. Age is
considered to be a cumulative risk factor for HBV infection
through blood, blood products, and sexual routes. A patient
with HCV aged 35 years had a history of blood transfusion,
indicating the possibility of transmission through this route.
In the present study, TB clinical manifestations were typical
of TB cases for the majority of pulmonary cases (197, 92.1%).
The frequency of extrapulmonary TB in this study was lowerted with HBV and HCV (N = 214).
Mean age Percentage (%)
43.25 ± 12.60 1.87
35 0.47
C virus.
Table 3 – Factors associated with hepatitis B virus infections among tuberculosis patients in Duhok Province, Kurdistan.
Variable HCV
patients (n)
HBV
patients (n)
Total
patients (n)
OR (95% CI)
(HBV patient)
p value
(HBV patients)
Age Age < 45 y 0 3 127 2.79 (0.28–66.88) 0.52
AgeP 45 y 1 1 87
Gender Male 1 3 136 1.78 (0.16–44.12) 0.63
Female 0 1 78
Educational status Uneducated 1 3 117 2.53 (0.23–64.10) 0.40
Educated 0 1 97
Marital status Married 1 2 148 0.44 (0.04–4.47) 0.41
Unmarried 0 2 66
Sexual practices Safe 0 3 202 6.03 (0.22–75.85) 0.09
Unsafe 1 1 12
History of blood transfusion Yes 1 1 25 2.58 (0.10–29.82) 0.09
No 0 3 189
History of injection drug use Yes 0 0 0 – –
No 1 4 214
Smoking Yes 1 3 145 1.44 (0.13–36.53) 0.75
No 0 1 69
Alcohol intake Yes 1 2 62 2.50 (0.24–25.43) 0.35
No 0 2 152
History of surgical operations Yes 0 2 45 3.88 (0.38–39.10) 0.15
No 1 2 169
History of dental intervention Yes 1 4 99 0.04 (–0.01–0.04) 0.03
No 0 0 115
Nationality Iraqi 1 3 208 13.67 (0.46–210.85) 0.007
Non-Iraqi 0 1 6
CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; OR, odds ratio; y, years.
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explained by the low prevalence of HIV infection in our local-
ity and the low prevalence of liver cirrhosis induced by viral
hepatitis [22].
With regard to risk factors, the history of dental interven-
tion and nationality in the present study were independent
risk factors for HBV/TB co-infection. We found that dental
treatment is a potential risk factor for HBV infection (OR,
0.04; 95% CI, 0.01 to 0.04; p = .03). In concordance with this
study, other works have documented similar findings
[23,24]. Viral hepatitis particles are well known to be present
in oral fluids; hence, they can be transmitted via saliva [25].
Generally, dental intervention by a professional dentist is
not a risk factor for HBV transmission; however, intervention
by an uncertified dentist can pose a risk [26]. Unqualified den-
tists are allegedly allowed to work in developing countries
[24]; standard precautionary measures are therefore needed
in dental treatment to reduce the risk of transmission. In
our study, Syrian nationality (data not shown) was signifi-
cantly associated with HBV/TB co-infection (OR, 13.67; 95%
CI, 0.46–210.85; p = .007). Syria is a country of intermediate
HBV endemicity [27]. Following internal conflict in Syria in
2011, many Syrian immigrants have fled its towns to the Kur-
distan region. These displaced refugees pose a potential risk
for HBV transmission in Kurdistan, particularly Duhok Pro-
vince. Similarly, Radun showed increased prevalence of HBV
in some parts of northern Europe due to migration of people
from intermediate- or high-HBV-prevalence countries [28]. It
is worth mentioning that TB patients with HBV/HCV co-
infection can develop complications due to chronic liver dis-
ease, which in turn can lead to interrupted TB treatment.Of particular concern are rifampicin, isoniazid, and pyrazi-
namide, which are among the first-line drugs. These are hep-
atotoxic drugs, which should be discontinued by patients
with deteriorated liver function due to liver disease [6]. Such
patients remain infectious and are more likely to experience
treatment failure and relapse, which may eventually threaten
the TB control program. Therefore, screening TB patients for
hepatotropic viruses that induce chronic liver disease may
be a valuable measure for reducing the side effects of hepato-
toxic anti-TB drugs.
Themain limitation in this studywas the small sample size;
furthermore, we did not determine whether patients were in
an active hepatitis state. The presence of significant liver
abnormality can result in deferred treatment and, subse-
quently, to poor treatment outcome. Another limitation was
the exclusion of HBV DNA and HCV RNA tests for patients
included in the study. This may affect the study results, as it
would allowearly diagnosis of hepatitis infections, particularly
in cases of occult hepatitis and, furthermore, in cases before
HBsAg or anti-HCVantibodies were detectable in blood.
In conclusion, the prevalence of HBVand HCV co-infection
among TB patients in this study was low. This may be
explained by the low rate of blood transfusion among the
patients, the very low prevalence of HIV in Kurdistan, the neg-
ative history for injection drug use, and adherence to univer-
sal infection-control measures, including vaccination for HBV.
Both history of dental intervention and nationality were inde-
pendent risk factors for HBV/TB co-infection. Further
prospective studies with larger sample size are needed to
ascertain the need for routine screening for HBsAg and anti-
HCV for HIV testing in TB patients.
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